Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
about
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Hypomethylating Agents as a Therapy for AML.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
P2860
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sequential azacitidine plus le ...... risk myelodysplastic syndrome.
@en
type
label
Sequential azacitidine plus le ...... risk myelodysplastic syndrome.
@en
prefLabel
Sequential azacitidine plus le ...... risk myelodysplastic syndrome.
@en
P2093
P2860
P1433
P1476
Sequential azacitidine plus le ...... risk myelodysplastic syndrome.
@en
P2093
Alex McMillan
Bruno C Medeiros
Camille Doykan
Caroline Berube
Charles Williamson
Jacqueline S Garcia
Jason Gotlib
Kathleen Regan
Mary-Elizabeth M Percival
Michael H Cardone
P2860
P304
P356
10.3109/10428194.2015.1091930
P577
2015-09-16T00:00:00Z